Center for Gastric Cancer, National Cancer Center, Goyang, Republic of Korea.
Cancer Policy Branch, National Cancer Control Institute, National Cancer Center, Goyang, Republic of Korea.
Surg Endosc. 2018 Apr;32(4):2114-2122. doi: 10.1007/s00464-017-5909-y. Epub 2017 Oct 24.
Endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) is expected to provide better long-term health-related quality of life (HRQOL) by preserving the entire stomach. We aimed to compare serial changes in HRQOL characteristics between patients who underwent ESD versus surgery for EGC.
A gastric cancer patient cohort was prospectively enrolled from 2004 to 2007. HRQOL of 161 EGC patients was prospectively assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30) and the stomach cancer-specific module EORTC-QLQ-STO22 at baseline (i.e., diagnosis) and at 1, 6, 12, 18, and 24 months of post-treatment.
Of 161 patients, 48 (29.8%) underwent ESD and 113 (70.2%) underwent surgery. HRQOL parameters of ESD patients were similar to or better than baseline values. At 1-month post-treatment, the surgery group had significantly poorer scores than the ESD group (P < 0.05) for factors except emotional and cognitive functioning, financial problems, anxiety, and hair loss. However, most of the HRQOL parameters in the surgery group improved during the first post-treatment year, with between-group differences becoming insignificant. Only five parameters (physical functioning, eating restriction, dysphagia, diarrhea, and body image) remained significantly better in the ESD group than the surgery group for > 1-year post-treatment (P < 0.05). The surgery group had significantly higher treatment-associated complications than the ESD group (15.0 vs. 2.1%; P = 0.017). The overall survival was not different between the both groups (5-year overall survival rates, 97.7% in the ESD group vs. 99.1% in the surgery group; P = 0.106 by the log-rank test).
Compared with surgery, ESD can provide better HRQOL benefits for EGC patients, especially during the early post-treatment period. However, surgical treatment should not be rejected only due to the concern about HRQOL impairments because most of them improved during follow-up periods.
内镜黏膜下剥离术(ESD)治疗早期胃癌(EGC)通过保留整个胃,有望提供更好的长期健康相关生活质量(HRQOL)。我们旨在比较 EGC 患者接受 ESD 与手术治疗的 HRQOL 特征的连续变化。
2004 年至 2007 年,前瞻性地招募了一个胃癌患者队列。使用欧洲癌症研究与治疗组织生活质量问卷核心 30 版(EORTC-QLQ-C30)和胃癌特异性模块 EORTC-QLQ-STO22 前瞻性评估 161 例 EGC 患者的 HRQOL,基线(即诊断)和治疗后 1、6、12、18 和 24 个月时。
在 161 例患者中,48 例(29.8%)接受 ESD 治疗,113 例(70.2%)接受手术治疗。ESD 患者的 HRQOL 指标与基线值相似或更好。在治疗后 1 个月,手术组除情绪和认知功能、经济问题、焦虑和脱发外,其他方面的评分均显著低于 ESD 组(P < 0.05)。然而,在治疗后的第一年,手术组的大多数 HRQOL 指标都有所改善,两组间的差异变得不显著。只有五个参数(身体功能、进食受限、吞咽困难、腹泻和身体形象)在治疗后 > 1 年时仍显著优于手术组(P < 0.05)。手术组的治疗相关并发症明显高于 ESD 组(15.0% vs. 2.1%;P = 0.017)。两组的总生存率无差异(ESD 组的 5 年总生存率为 97.7%,手术组为 99.1%;对数秩检验 P = 0.106)。
与手术相比,ESD 可为 EGC 患者提供更好的 HRQOL 获益,尤其是在早期治疗后期间。然而,不应仅仅因为担心 HRQOL 受损而拒绝手术治疗,因为大多数在随访期间得到改善。